From: Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis
Variable | No Statins | Statins | p-value |
---|---|---|---|
Females: Males (% Female) | 301: 81 (78.8%) | 69: 40 (63.3%) | < 0.002§ |
MS course: |  |  | 0.075‡ |
Relapsing-remitting | 314 | 81 (74.3%) | Â |
Secondary progressive | (82.2%) | Â | Â |
Primary progressive | 55 (12.8%) 13 (3.4%) | 27 (24.8%) 1 (0.9%) | Â |
Age*, years | 45.3 ± 10.7 | 53.4 ± 8.4 | < 0.001 |
Disease duration*, years | 11.9 ± 9.7 | 16.2 ± 11.0 | < 0.001 |
Median EDSS* (IQR) | 2.5 (2.0) | 3.50 (3.50) | < 0.001# |
MSSS | 3.67 ± 2.51 | 4.15 ± 2.18 | 0.061 |
Time to follow-up, years | 2.13 ± 1.0 | 2.22 ± 1.0 | 0.43 |
Body mass index, kg/m2 | 27.4 ± 6.5 | 29.1 ± 6.5 | 0.013¶ |
HDL, mg/dL | 55.6 ± 16.6 | 53.7 ± 16.5 | 0.72¶ |
LDL, mg/dL | 115 ± 30.8 | 118 ± 39.0 | 0.62¶ |
Total cholesterol, mg/dL | 196 ± 36.0 | 201 ± 44.7 | 0.38¶ |
Triglycerides, mg/dL | 128 ± 84.0 | 149 ± 75.5 | 0.15¶ |
Cholesterol to HDL ratio | 3.81 ± 1.28 | 4.00 ± 1.40 | 0.60¶ |
Presence of CEL CEL number CE-LV, cm3 | 25/156 (16%) 0.60 ± 2.3 0.035 ± 0.15 | 4/40 (10%) 0.23 ± 0.86 0.019 ± 0.080 | 0.47¶ 0.026¶ 0.035¶ |
T2-LV, cm3 | 13.6 ± 14.7 | 16.0 ± 14.7 | 0.30¶ |
T1-LV, cm3 | 2.7 ± 5.1 | 4.5 ± 6.3 | 0.019¶ |
BPF | 0.858 ± 0.027 | 0.848 ± 0.035 | 0.056¶ |